Evidence map›Paper›PMID 34267757›Full record

Trial reportFrontiers in immunology2021

Baseline CD3+CD56+ (NKT-like) Cells and the Outcome of Influenza Vaccination in Children Undergoing Chemotherapy.

Evelin A Leibinger, Gábor Pauler, Noémi Benedek, Tímea Berki, István Jankovics, Richard McNally, Gábor Ottóffy

Abstract readClinical Trial
In one paragraph

Trial report in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Evelin A LeibingerDivision of Pediatric Hematology and Oncology, Department of Pediatrics, University of Pécs Medical School, Pécs, Hungary.
Gábor PaulerInstitute of Mathematics and Informatics, University of Pécs, Pécs, Hungary.
Noémi BenedekDivision of Pediatric Hematology and Oncology, Department of Pediatrics, University of Pécs Medical School, Pécs, Hungary.
Tímea BerkiDepartment of Immunology and Biotechnology, University of Pécs Medical School, Pécs, Hungary.
István JankovicsDepartment of Virology, National Center for Epidemiology, Budapest, Hungary.
Richard McNallyPopulation Health Sciences Institute, Newcastle University, Newcastle, United Kingdom.
Gábor OttóffyDivision of Pediatric Hematology and Oncology, Department of Pediatrics, University of Pécs Medical School, Pécs, Hungary.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In children undergoing chemotherapy yearly influenza vaccination is recommended by treatment protocols. We investigated the relationship between cellular immunity and the antibody response to inactivated influenza vaccines. Methods: 25 patients (age: 2-18 years) undergoing chemotherapy for different malignancies participated in our study. Flow cytometric detection of peripheral blood lymphocyte subpopulations together with hemagglutination inhibition antibody titers were measured before and 21-28 days after vaccination. We examined the ratio and total numbers of CD3+, CD4+, CD8+ T cells, activated helper (CD3+CD4+CD25 Results: Patients with CD4+ lymphocyte levels in the normal age-specific range showed significantly better response regarding postvaccination GMT elevation for H1N1 and H3N2 strains (97.52 Conclusions: In addition to verifying the predictive value of absolute lymphocyte count above 1000/µl, our results suggest an association between NKT-like cell counts and the specific antibody response against all three investigated influenza strains in highly immunosuppressed patients. Furthermore, prevaccination CD4+ lymphocyte levels in the normal age-specific range may influence seroresponse.

Indexed as

AdolescentAntibodies, ViralAntineoplastic AgentsCD3 ComplexCD4-Positive T-LymphocytesCD56 AntigenChildChild, PreschoolFemaleHumansInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeInfluenza, HumanInfluenza VaccinesLymphocyte CountMaleAntibodies, ViralAntineoplastic AgentsCD3 ComplexCD56 AntigenInfluenza VaccinesNCAM1 protein, humanVaccines, InactivatedCD4+ T-cellscellular immunityimmunosuppressioninfluenza vaccineslymphocyte subsetsnatural killer T-cellspediatrics

Identifiers

PMID34267757
PMCPMC8276261

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.